[Special Stock] FromBio, Next-Generation Stem Cell Hair Loss Treatment New Technology... "Commercialization for 10 Million Hair Loss Population"

[Asia Economy Reporter Hyungsoo Park] FromBio is showing strong performance. The stock price appears to be influenced by the disclosure of new hair loss treatment technology using adipose-derived stem cells.

As of 1:34 PM on the 25th, FromBio is trading at 8,210 KRW, up 14.19% from the previous day.

FromBio announced the day before that it held a session on new hair loss treatment technology using stem cells at the '2022 Korean Society of Food and Nutrition Science International Symposium and Annual Conference.'

The new technology developed by FromBio is characterized by maintaining the inherent properties of stem cells while supporting stable growth and proliferation. It explained that this technology demonstrates excellent efficacy in developing hair loss treatments while reducing genetic side effects and immune rejection reactions. It added that the new technology is gaining attention as the next-generation hair loss treatment.

FromBio has achieved outstanding research results related to hair loss treatment, including registering a patent on the 5th for a method of culturing dermal papilla cells that promote hair growth.

Shim Tae-jin, CEO of FromBio, said, "Based on the technology and expertise accumulated over a long period, we were able to complete FromBio's differentiated technology for developing hair loss treatments," adding, "We will continue to actively invest to commercialize stem cell hair loss treatments for the 10 million hair loss population."

This content was produced with the assistance of AI translation services.